CHA ÀǰúÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • À¯ÁØÈ¯
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ¿°Áõ¼ºÀåÁúȯ, ´ëÀå¾Ï, Ä¡·á³»½Ã°æ
  • Á÷ À§: ºÎ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
270 (±¹¿Ü)SCIE Anti-fibrogenic effect of PPAR-¥ã agonists in human intestinal myofibroblasts
269 (±¹¿Ü)SCIE Low Serum Pancreatic Amylase and Lipase Values Are Simple and Useful Predictors to Diagnose Chronic Pancreatitis
268 (±¹³»)SCOPUS Prediction and Prevention of Postpolypectomy Bleeding: Necessity of a Different Approach for Patients Using Antithrombotic Agents
267 (±¹¿Ü)SCIE Role of Computed Tomography Volumetry in Estimating Liver Weights in Surgical Patients with Hepatic Steatosis
266 (±¹¿Ü)SCI Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective
265 (±¹¿Ü)SCI Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir
264 (±¹¿Ü)SCI The Stent Patency and Migration Rate of Different Shaped Plastic Stents in Bile Flow Phantom Model and In Vivo Animal Bile Duct Dilation Model
263 (±¹¿Ü)SCI Gastroesophageal reflux after peroral endoscopic myotomy: a multicenter case?control study
262 (±¹³»)SCIE Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
261 (±¹³»)SCIE Comparison of the Outcomes of Peroral Endoscopic Myotomy for Achalasia According to Manometric Subtype
ÀÌÀüÆäÀÌÁö À̵¿ 21 22 23 24 25 26 27 28 29 30 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾Çհǰ­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729